Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis |
| |
| Institution: | 1. Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece;2. First Department of Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece;3. Division of General Internal Medicine, University Hospital Inselspital of Bern, 3010 Bern, Switzerland;4. Department of Nutrition and Dietetics, Alexander Technological Educational Institute, Thessaloniki, Sindos, Macedonia, Greece;5. Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Macedonia, Greece;6. Agios Pavlos General Hospital, Thessaloniki, Macedonia, Greece;7. St. Elisabeth-Hospital Herten GmbH, Herten, Germany;8. Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;1. QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal;2. Unidade de Investigação Cardiovascular, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal;3. iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal;4. Department of Applied Physiology and Kinesiology, University of Florida, United States;5. CIAFEL, Faculty of Sport, University of Porto, Porto, Portugal;1. Laboratory of Biochemistry, University of Crete School of Medicine, Heraklion, Greece;2. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion, Greece;3. Section of Molecular Genetics, Boston University Medical School, Boston, USA;4. 4th Department of Internal Medicine, “Attikon” Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece;1. Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, PR China;2. Center of Diabetic Systems Medicine, Guilin Medical University, Guilin, Guangxi, PR China;3. Department of laboratory medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, PR China;4. Department of Epidemiology and Health Statistics, Guilin Medical University, Guilin, Guangxi, PR China;5. Research Center of Combined Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, PR China;6. Department of Human Anatomy, Southwest Medical University, Luzhou, Sichuan, PR China;7. Medical Examination Center, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, PR China;1. Institute of Health and Biomedical Innovation, School of Exercise and Nutrition Sciences, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia;2. School of Health Sciences, College of Health and Medicine, University of Tasmania, Newnham, TAS 7248, Australia;1. Laboratory of Metabolism, Department of Medicine Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland;2. Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland;3. Center for Integrative Genomics, University of Lausanne, Le Génopode, 1015 Lausanne, Switzerland;4. Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, 308232, Singapore;1. Department of Endocrinology, VA Boston Healthcare System, Jamaica Plain, Boston, MA 02130, USA;2. Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA;3. Division of Applied Mathematics, Brown University, Providence, RI 02906, USA |
| |
| Abstract: | Both Helicobacter pylori infection and metabolic syndrome present significant global public health burdens. Metabolic syndrome is closely related to insulin resistance, the major underlying mechanism responsible for metabolic abnormalities, and Helicobacter pylori infection has been proposed to be a contributing factor. There is growing evidence for a potential association between Helicobacter pylori infection and insulin resistance, metabolic syndrome and related morbidity, including abdominal obesity, type 2 diabetes mellitus, dyslipidemia, hypertension, all of which increase mortality related to cardio-cerebrovascular disease, neurodegenerative disorders, nonalcoholic fatty liver disease and malignancies. More specifically, insulin resistance, metabolic syndrome and hyperinsulinemia have been associated with upper and lower gastrointestinal tract oncogenesis. Apart from cardio-cerebrovascular, degenerative diseases and nonalcoholic fatty liver disease, a number of studies claim that Helicobacter pylori infection is implicated in metabolic syndrome-related Barrett's esophagus and esophageal adenocarcinoma development, gastric and duodenal ulcers and gastric oncogenesis as well as lower gastrointestinal tract oncogenesis. This review summarizes evidence on the potential impact of Helicobacter pylori-related metabolic syndrome on gastroesophageal reflux disease-Barrett's esophagus-esophageal adenocarcinoma, gastric atrophy-intestinal metaplasia-dysplasia-gastric cancer and colorectal adenoma-dysplasia-colorectal cancer sequences. Helicobacter pylori eradication might inhibit these oncogenic processes, and thus further studies are warranted. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
